The positive outcome from the Phase 1b study of ALKS 2680 directly impacts Alkermes by potentially increasing investor confidence and interest in the company's stock. Given the significance of new drug developments in the biotech sector, such positive results are likely to have a favorable impact on the company's stock price in the short term, as they indicate progress in the company's pipeline and potential for future revenue growth.